Shanghai ChemPartner, a leading life science organization providing high-quality and cost-effective drug discovery and development services, recently announced the closure of the merger deal with Quantum Hi-Tech China Biological.

Michael Hui will remain the Chairman of the Shanghai ChemPartner, and will serve as the Vice Chairman of the Quantum Board of Directors.  The ChemPartner leadership team will remain intact, and the company will continue to operate as a standalone entity.

Shanghai ChemPartner, which includes ChemPartner, China Gateway Pharmaceutical Development, China Gateway Biologics, and ChemExplorer, offers a broad range of drug discovery and development capabilities including biologics discovery, chemistry and medicinal chemistry, biology and pharmacology, DMPK and exploratory toxicology, and small and large molecule CMC (Chemistry, Manufacturing, and Controls).  Shanghai ChemPartner serves a diverse global client base and has laboratories, business offices and representatives in the US, Europe, China, and Japan.